{"id":35263,"date":"2025-06-16T15:14:08","date_gmt":"2025-06-16T07:14:08","guid":{"rendered":"https:\/\/flcube.com\/?p=35263"},"modified":"2025-06-16T15:14:09","modified_gmt":"2025-06-16T07:14:09","slug":"roche-imposes-new-dosing-restrictions-on-elevidys-for-non-ambulatory-dmd-patients","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35263","title":{"rendered":"Roche Imposes New Dosing Restrictions on Elevidys for Non-Ambulatory DMD Patients"},"content":{"rendered":"\n

Swiss pharmaceutical giant Roche AG (SWX: ROG<\/a>, OTCMKTS: RHHBY<\/a>) announced immediate new dosing restrictions for Elevidys (delandistrogene moxeparvovec) in Duchenne muscular dystrophy (DMD) patients who are non-ambulatory, regardless of age. This applies to both clinical and commercial settings.<\/p>\n\n\n\n

New Restrictions<\/strong>
In the commercial setting, non-ambulatory patients will no longer receive Elevidys treatment. In clinical trial settings, enrollment and dosing for non-ambulatory patients will be suspended immediately until additional risk mitigation measures, such as immunomodulatory therapy, are implemented in the study protocols.<\/p>\n\n\n\n

Drug Background<\/strong>
Elevidys is a recombinant gene therapy that uses an AAV viral vector to deliver a transgene encoding micro-dystrophin. Administered via a single intravenous infusion, it enables patients’ muscles to produce a recombinant protein with partial dystrophin functionality. It is effective for patients with any type of DMD-causing genetic variant.<\/p>\n\n\n\n

Regulatory Context<\/strong>
In March 2025, the European Medicines Agency (EMA) paused Elevidys’ Phase III clinical trial in Europe following the death of a patient who did not meet the study criteria. The patient developed acute liver failure (ALF) after receiving Elevidys. The decision to adjust dosing was prompted by this incident, as acute liver failure is a known risk of Elevidys and other AAV-mediated gene therapies.<\/p>\n\n\n\n

Benefit-Risk Reassessment<\/strong>
The new dosing restrictions reflect a reassessment of the benefit-risk ratio for non-ambulatory DMD patients, which is now deemed unfavorable. However, the restrictions do not affect treatment for ambulatory DMD patients of any age, where the benefit-risk ratio remains positive.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Swiss pharmaceutical giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced immediate new dosing restrictions for…<\/p>\n","protected":false},"author":1,"featured_media":35264,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[66,940,24,163,939],"class_list":["post-35263","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-gene-therapy","tag-otcmkts-rhhby","tag-rare-orphan-disease-drugs","tag-roche","tag-swx-rop"],"yoast_head":"\nRoche Imposes New Dosing Restrictions on Elevidys for Non-Ambulatory DMD Patients - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Swiss pharmaceutical giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced immediate new dosing restrictions for Elevidys (delandistrogene moxeparvovec) in Duchenne muscular dystrophy (DMD) patients who are non-ambulatory, regardless of age. This applies to both clinical and commercial settings.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35263\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche Imposes New Dosing Restrictions on Elevidys for Non-Ambulatory DMD Patients\" \/>\n<meta property=\"og:description\" content=\"Swiss pharmaceutical giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced immediate new dosing restrictions for Elevidys (delandistrogene moxeparvovec) in Duchenne muscular dystrophy (DMD) patients who are non-ambulatory, regardless of age. This applies to both clinical and commercial settings.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35263\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-16T07:14:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-16T07:14:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1610.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35263#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35263\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Roche Imposes New Dosing Restrictions on Elevidys for Non-Ambulatory DMD Patients\",\"datePublished\":\"2025-06-16T07:14:08+00:00\",\"dateModified\":\"2025-06-16T07:14:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35263\"},\"wordCount\":254,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35263#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1610.webp\",\"keywords\":[\"Gene therapy\",\"OTCMKTS: RHHBY\",\"Rare \\\/ orphan disease drugs\",\"Roche\",\"SWX: ROP\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35263#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35263\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35263\",\"name\":\"Roche Imposes New Dosing Restrictions on Elevidys for Non-Ambulatory DMD Patients - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35263#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35263#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1610.webp\",\"datePublished\":\"2025-06-16T07:14:08+00:00\",\"dateModified\":\"2025-06-16T07:14:09+00:00\",\"description\":\"Swiss pharmaceutical giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced immediate new dosing restrictions for Elevidys (delandistrogene moxeparvovec) in Duchenne muscular dystrophy (DMD) patients who are non-ambulatory, regardless of age. This applies to both clinical and commercial settings.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35263#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35263\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35263#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1610.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1610.webp\",\"width\":1080,\"height\":608,\"caption\":\"Roche Imposes New Dosing Restrictions on Elevidys for Non-Ambulatory DMD Patients\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35263#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Roche Imposes New Dosing Restrictions on Elevidys for Non-Ambulatory DMD Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roche Imposes New Dosing Restrictions on Elevidys for Non-Ambulatory DMD Patients - Insight, China's Pharmaceutical Industry","description":"Swiss pharmaceutical giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced immediate new dosing restrictions for Elevidys (delandistrogene moxeparvovec) in Duchenne muscular dystrophy (DMD) patients who are non-ambulatory, regardless of age. This applies to both clinical and commercial settings.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35263","og_locale":"en_US","og_type":"article","og_title":"Roche Imposes New Dosing Restrictions on Elevidys for Non-Ambulatory DMD Patients","og_description":"Swiss pharmaceutical giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced immediate new dosing restrictions for Elevidys (delandistrogene moxeparvovec) in Duchenne muscular dystrophy (DMD) patients who are non-ambulatory, regardless of age. This applies to both clinical and commercial settings.","og_url":"https:\/\/flcube.com\/?p=35263","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-16T07:14:08+00:00","article_modified_time":"2025-06-16T07:14:09+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1610.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35263#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35263"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Roche Imposes New Dosing Restrictions on Elevidys for Non-Ambulatory DMD Patients","datePublished":"2025-06-16T07:14:08+00:00","dateModified":"2025-06-16T07:14:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35263"},"wordCount":254,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35263#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1610.webp","keywords":["Gene therapy","OTCMKTS: RHHBY","Rare \/ orphan disease drugs","Roche","SWX: ROP"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35263#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35263","url":"https:\/\/flcube.com\/?p=35263","name":"Roche Imposes New Dosing Restrictions on Elevidys for Non-Ambulatory DMD Patients - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35263#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35263#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1610.webp","datePublished":"2025-06-16T07:14:08+00:00","dateModified":"2025-06-16T07:14:09+00:00","description":"Swiss pharmaceutical giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced immediate new dosing restrictions for Elevidys (delandistrogene moxeparvovec) in Duchenne muscular dystrophy (DMD) patients who are non-ambulatory, regardless of age. This applies to both clinical and commercial settings.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35263#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35263"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35263#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1610.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1610.webp","width":1080,"height":608,"caption":"Roche Imposes New Dosing Restrictions on Elevidys for Non-Ambulatory DMD Patients"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35263#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Roche Imposes New Dosing Restrictions on Elevidys for Non-Ambulatory DMD Patients"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1610.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35263","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35263"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35263\/revisions"}],"predecessor-version":[{"id":35265,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35263\/revisions\/35265"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/35264"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35263"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35263"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}